(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents in Japan and internationally...
Stats | |
---|---|
本日の出来高 | 58 300.00 |
平均出来高 | 65 186.00 |
時価総額 | 93.41B |
EPS | ¥0 ( 2024-01-31 ) |
次の収益日 | ( ¥0 ) 2024-05-09 |
Last Dividend | ¥22.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 10.81 |
ATR14 | ¥1.494 (0.07%) |
ボリューム 相関
Zeria Pharmaceutical Co., 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Zeria Pharmaceutical Co., 相関 - 通貨/商品
Zeria Pharmaceutical Co., 財務諸表
Annual | 2022 |
収益: | ¥68.38B |
総利益: | ¥49.49B (72.37 %) |
EPS: | ¥140.26 |
FY | 2022 |
収益: | ¥68.38B |
総利益: | ¥49.49B (72.37 %) |
EPS: | ¥140.26 |
FY | 2022 |
収益: | ¥59.53B |
総利益: | ¥42.15B (70.80 %) |
EPS: | ¥87.76 |
FY | 2021 |
収益: | ¥55.43B |
総利益: | ¥39.63B (71.50 %) |
EPS: | ¥67.72 |
Financial Reports:
No articles found.
Zeria Pharmaceutical Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥18.00 (N/A) |
¥0 (N/A) |
¥22.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥7.27 | 2001-03-27 |
Last Dividend | ¥22.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 46 | -- |
Total Paid Out | ¥532.64 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.85 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.56 | |
Div. Directional Score | 7.95 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8537.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7860.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7003.T | Ex Dividend Junior | 2024-03-28 | Sporadic | 0 | 0.00% | |
6356.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5210.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
4318.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3482.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
2695.T | Ex Dividend Junior | 2023-10-30 | Annually | 0 | 0.00% | |
9065.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8151.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.116 | 1.500 | 7.68 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0564 | 1.200 | 8.12 | 9.74 | [0 - 0.3] |
returnOnEquityTTM | 0.121 | 1.500 | 9.77 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.086 | 0.800 | 9.57 | 7.66 | [1 - 3] |
quickRatioTTM | 0.787 | 0.800 | -0.0759 | -0.0607 | [0.8 - 2.5] |
cashRatioTTM | 0.350 | 1.500 | 9.17 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.331 | -1.500 | 4.48 | -6.73 | [0 - 0.6] |
interestCoverageTTM | 23.81 | 1.000 | 2.29 | 2.29 | [3 - 30] |
operatingCashFlowPerShareTTM | 313.62 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 313.62 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.646 | -1.500 | 7.42 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.739 | 1.000 | 1.016 | 1.016 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.133 | 1.000 | 9.33 | 9.33 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.273 | 1.000 | 9.60 | 9.60 | [0.2 - 2] |
assetTurnoverTTM | 0.487 | 0.800 | -0.0854 | -0.0683 | [0.5 - 2] |
Total Score | 10.34 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 10.81 | 1.000 | 9.01 | 0 | [1 - 100] |
returnOnEquityTTM | 0.121 | 2.50 | 9.85 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 313.62 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.08 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 313.62 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.378 | 1.500 | -0.817 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.185 | 1.000 | 7.87 | 0 | [0.1 - 0.5] |
Total Score | 5.56 |
Zeria Pharmaceutical Co.,
Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents in Japan and internationally. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn's disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; sclerosing agent for varicose veins; anti-inflammatory topical blood circulation enhancers; non-steroidal anti-inflammatory ophthalmic solutions; absorbable topical hemostat products; and proton pump inhibitors. In addition, it offers consumer healthcare products, such as nutritional health drugs, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, and food for specified health uses. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。